Should Pfizer's Strong Quarter Calm Investor Concerns About the Stock?
Demand for COVID-19 vaccines and drugs has been fading for a while now. And that has put a big dent in 's (NYSE: PFE) sales and profit numbers. On top of that, the stock is also facing headwinds due to losses in exclusivity for multiple drugs, which threaten to wipe off billions of dollars in revenue from its top line this decade.
Recently, however, Pfizer reported some encouraging quarterly numbers. Also, the growth rate of many drugs was in double digits. The performance was good enough for the company to justify raising its guidance for the year. Is this a sign that perhaps Pfizer isn't in as bad a shape as investors may have been worrying?
Could now be a good time to add the healthcare stock to your portfolio?
Source Fool.com
Pfizer Inc. Stock
€26.15
-0.650%
The stock is one of the favorites of our community with 29 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 56.82% compared to the current price of 26.15 € for Pfizer Inc..
